Key Highlights
- Net loss per share was USD 2.83 against an estimate of a USD 1.08 loss.
- Revenue was USD 55,463, compared with USD 15,606.
- Net loss was USD 3.22 million, compared with USD 4.55 million.
- Cash and cash equivalents were USD 0.96 million at September 30, 2026.
HCW Biologics (NASDAQ:HCWB) reported Revenue of USD 55,463 for the third quarter of 2026, compared with USD 15,606 in the third quarter of 2025. The net loss was USD 3.22 million, compared with USD 4.55 million, and the basic and diluted net loss per share was USD 2.83, compared with USD 12.09, against an estimate of a USD 1.08 loss.
The filing states that third quarter revenue related to the completion of some of the services required under the service performance obligation for the Trimmune license, primarily supporting Trimmune with building a master cell bank.
Operating Results
Cost of revenues was USD 27,345, and Gross Profit was USD 28,118, compared with USD 3,121. Research and Development expense was USD 1.24 million, compared with USD 1.40 million, and general and administrative expense was USD 1.37 million, compared with USD 1.88 million. Total operating expenses were USD 2.62 million, compared with USD 3.30 million, and the operating loss was USD 2.59 million, compared with USD 3.29 million.
The quarter also included a loss on return of equipment of USD 0.49 million. An Equity Dividend to investors of USD 2.72 million brought the net loss attributable to common stockholders to USD 5.94 million, compared with USD 4.55 million.
Nine-Month Results
For the nine months ended September 30, 2026, revenue was USD 6.73 million, compared with USD 27,222, and gross profit was USD 6.47 million. On March 16, 2026, the company received full payment of the nonrefundable upfront license fee from Beijing Trimmune Biotech. Research and development expense was USD 3.70 million, compared with USD 4.11 million, and general and administrative expense was USD 5.07 million, compared with USD 6.19 million.
The operating loss was USD 2.52 million, compared with USD 8.70 million, and the net loss was USD 4.97 million, compared with USD 8.68 million. The net loss per share was USD 13.35, compared with USD 68.02.
Balance Sheet and Going Concern
Cash and cash equivalents were USD 0.96 million at September 30, 2026, compared with USD 1.95 million at December 31, 2025. Investments were USD 4.85 million, compared with USD 1.33 million, and property, plant and equipment, net, was USD 18.96 million, compared with USD 20.88 million. Total Assets were USD 25.13 million, compared with USD 24.52 million.
Accounts payable were USD 9.44 million, compared with USD 13.14 million, and total liabilities were USD 18.30 million, compared with USD 21.76 million. Total stockholders' equity was USD 6.82 million, compared with USD 2.76 million.
The filing states that cumulative net losses since inception were USD 110.8 million, and that management believes substantial doubt exists regarding the company's ability to continue as a Going Concern for at least 12 months from the issuance date of the financial statements and was not alleviated.
HCW Biologics Q3 2026 Earnings: Key Takeaways
HCW Biologics reported third quarter 2026 revenue of USD 55,463 and a net loss of USD 3.22 million. Cash and cash equivalents were USD 0.96 million at September 30, 2026.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...